Literature DB >> 8254093

Cerebrospinal fluid concentration of fibronectin in patients with HIV-1 infection and central nervous system disorders.

D Torre1, C Zeroli, G Ferrario, G Bonetta, G P Fiori, R Martegani.   

Abstract

AIMS: To evaluate the fibronectin concentrations in the cerebrospinal fluid of HIV-1 infected patients with central nervous system disorders.
METHODS: Fibronectin was determined by an immunoturbidimetric assay in 41 HIV-1 infected patients with AIDS dementia complex, progressive multifocal leucoencephalopathy, and opportunistic infections.
RESULTS: A significant decrease in fibronectin concentrations in the cerebrospinal fluid of patients with AIDS and dementia complex and progressive multifocal leucoencephalopathy was observed, as well as in those with opportunistic infections of the central nervous system (p < 0.0001). In particular, a significant decrease in fibronectin concentration in cerebrospinal fluid was observed in patients with cerebral toxoplasmosis and cryptococcal meningitis (p < 0.0001).
CONCLUSIONS: Because fibronectin can bind to several viruses, fungi, and protozoa, it is conceivable to suppose that the consumption of fibronectin in the cerebrospinal fluid of patients with neurological disorders may be related to the binding of fibronectin to HIV itself, or to viral proteins, or to organisms responsible for opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254093      PMCID: PMC501691          DOI: 10.1136/jcp.46.11.1039

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  Functional hyposplenism during pneumococcal infection.

Authors:  B J Boughton; A Simpson; S Chandler
Journal:  Lancet       Date:  1983-01-15       Impact factor: 79.321

Review 2.  Fibronectin: current concepts of its structure and functions.

Authors:  E Ruoslahti; E Engvall; E G Hayman
Journal:  Coll Relat Res       Date:  1981

3.  Demonstration of fibronectin in human cerebrospinal fluid.

Authors:  P Kuusela; A Vaheri; J Palo; E Ruoslahti
Journal:  J Lab Clin Med       Date:  1978-10

4.  Plasma fibronectin in acute leukaemia.

Authors:  B J Boughton; A Simpson
Journal:  Br J Haematol       Date:  1982-07       Impact factor: 6.998

5.  In vitro binding of Candida albicans yeast cells to human fibronectin.

Authors:  K G Skerl; R A Calderone; E Segal; T Sreevalsan; W M Scheld
Journal:  Can J Microbiol       Date:  1984-02       Impact factor: 2.419

6.  Role of fibronectin in human monocyte and macrophage bactericidal activity.

Authors:  R A Proctor; J A Textor; J M Vann; D F Mosher
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

7.  Fibronectin increases the motility, phagocytosis and NBT (nitroblue tetrazolium)-reduction of granulocytes.

Authors:  C Jarstrand; T Ahlgren; L Berghem
Journal:  J Clin Lab Immunol       Date:  1982-05

8.  Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation.

Authors:  D F Mosher; E M Williams
Journal:  J Lab Clin Med       Date:  1978-05

9.  Fibronectin is expressed by astrocytes cultured from embryonic and early postnatal rat brain.

Authors:  P Liesi; T Kirkwood; A Vaheri
Journal:  Exp Cell Res       Date:  1986-03       Impact factor: 3.905

10.  Cerebrospinal fluid concentration of fibronectin in meningitis.

Authors:  D Torre; C Zeroli; M Issi; G P Fiori; G Ferraro; F Speranza
Journal:  J Clin Pathol       Date:  1991-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.